Compare

Vitrolife AB/Skr VITR

1D1W1M3M6MYTD1Y5YMAX

About Vitrolife AB

Vitrolife AB is a biotechnology company that operates in the fertility treatment industry, providing products and services designed to support in vitro fertilization (IVF). The company's portfolio includes culture media, IVF disposable devices, and time-lapse systems for embryo assessment. Founded in 1994, Vitrolife has developed a strong presence in the field of reproductive health by focusing on improving clinical results and patient outcomes. Headquartered in Gothenburg, Sweden, the company serves customers globally, with manufacturing facilities and offices across Europe, the Americas, and Asia. Vitrolife's strategic focus on research and development, along with its commitment to quality and innovation, positions it as a significant player in the global IVF market.
Ticker
Skr VITR
Sector
Health
Primary listing
XSTO
Employees
1,088
Headquarters
Gothenburg, Sweden
Website
www.vitrolife.com

Vitrolife AB Metrics

BasicAdvanced
kr 15B
-
-kr 36.70
1.67
kr 1.10
0.95%

What the Analysts think about Vitrolife AB

Analyst ratings (Buy, Hold, Sell) for Vitrolife AB stock.
Analyst projections of the future price of Vitrolife AB stock.

Bulls say / Bears say

Third-quarter organic growth accelerated to 6% excluding exited product lines, with Technologies up 21% across all regions. Vitrolife also shipped a record number of EmbryoScopes, suggesting the equipment business is gaining traction. (Vitrolife, Redeye)
Profitability is improving: nine-month gross margin rose to 59.8% from 58.1%, while EBITDA increased to SEK 825 million from SEK 753 million. This indicates that its restructuring and focus on higher-margin products are helping earnings, even as sales growth remains modest. (Vitrolife)
Vitrolife has broadened its product range with EmbryoCath and EmbryoViewer Pro, and says its share of sales from recently launched products is at a record high. Management expects 2027 to be its strongest year for product launches, giving the company further opportunities to grow sales. (Seeking Alpha, StockAnalysis)
China’s IVF cycles remain below last year and management expects weakness to persist into 2027, citing structural demographic pressures. China is Vitrolife’s largest APAC market, making a prolonged downturn a material growth risk. (Seeking Alpha)
Demand in the Middle East is still subdued, with IVF activity depressed despite early signs of improvement. That leaves Vitrolife exposed to a regional recovery that has yet to translate into a clear return in routine clinic demand. (Investing.com)
Underlying profitability may be less strong than the reported figures suggest: Redeye estimated Q3 adjusted EBITDA margin at 30.5%, below expectations, as higher material costs and wage inflation offset restructuring savings. This could limit further margin gains if cost pressures persist. (Redeye)
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2026.

Vitrolife AB Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Vitrolife AB Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Vitrolife AB

AllUSDEURGBP
Funds
Fund name
Fund size
Skr VITR weighting
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.05%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.05%
iShares MSCI World Small Cap£WLDS
$9B0.01%
iShares MSCI World Small Cap€IUSN
$9B0.01%
iShares MSCI World Small Cap$WSML
$9B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.